Articles tagged with Lung Cancer
The ALEX trial demonstrates alectinib's superiority over crizotinib as first-line therapy for ALK-positive non-small cell lung cancer, with improved progression-free survival and brain metastasis outcomes. Alectinib achieved a 53% reduction in progression risk and 68.4% one-year progression-free rate compared to crizotinib.
A phase III clinical trial found that alectinib, a next-generation ALK inhibitor, extended the median time to progression by about 15 months compared to crizotinib. Alectinib also caused fewer severe side effects and was more effective in preventing brain metastases.
A phase III clinical trial suggests a potential new treatment for patients with advanced EGFR-positive non-small cell lung cancer. Dacomitinib delayed cancer growth by 5.5 months compared to gefitinib, but also caused more side effects.
BU researcher Avrum Spira recognized for his work on early detection of lung cancer using Percepta RNA biomarker, as well as development of new drugs for chronic obstructive pulmonary disease (COPD). His research has made a direct impact on diagnosis and daily care of patients with lung cancer and COPD in the past 20 years.
Researchers at UT Southwestern Medical Center have identified a 35-gene signature that indicates higher genetic likelihood of chemotherapy resistance in non-small cell lung cancer. This biomarker can help predict relapse and provide a new pharmacologic approach to target chemo-resistant lung cancer.
A new study suggests that 'light' cigarettes have no health benefits and may contribute to the rise of lung adenocarcinoma. The FDA should regulate the use of ventilation holes on cigarettes to reduce the risk of this type of cancer, according to experts.
Lung cancer patients are susceptible to malignant pleural effusion, a build-up of excess fluid that can cause shortness of breath and chest pain. Researchers have discovered a novel mechanism that causes this condition, which could lead to the development of new treatments targeting the KRAS-mutant cancer cells.
A phase III clinical trial shows gefitinib is effective in preventing recurrence after lung cancer surgery, with patients going about 10 months longer without disease-free survival. The treatment causes far fewer side effects compared to chemotherapy, with only 12% experiencing severe side effects versus 48%.
The FDA approves brigatinib as a second-line therapy for ALK-positive non-small cell lung cancer, demonstrating a 54% response rate and 12.9-month progression-free survival. Brigatinib's longer control duration compared to other next-generation ALK inhibitors suggests its broader spectrum of coverage against resistance mechanisms.
Researchers developed a prototype drug that directly activates a tumor suppressor protein, preventing lung cancer tumors in mice. The study's findings suggest the potential for broad applicability to various human cancers, including breast, prostate, and childhood cancers.
Lung cancer cells in an invasive pack have specialized roles as leaders and followers, which depend on each other for mobility and survival. The leader-follower symbiosis could be a key target for future treatments aimed at impairing or preventing cancer metastasis.
Researchers discovered that blocking this Wnt pathway prevents tumor growth and prolongs mouse lifespan. Human lung adenocarcinoma samples also showed high levels of Wnt activation.
Researchers at the University of Cincinnati have engineered a cancer stem cell vaccine that expresses pro-inflammatory protein IL-15 and its receptor to stimulate T cell production. This results in enhanced immune responses against tumors with reduced side effects, offering potential new immunotherapy treatments.
A recent study found that East German women are at a higher risk of death from smoking due to insufficient anti-smoking policies. The researchers forecast a significant increase in mortality rates for these women, mainly due to lung cancer and other smoking-related diseases.
A study published in JAMA found that using a combination of docetaxel and selumetinib did not improve progression-free or overall survival for patients with KRAS-mutant non-small cell lung cancer. The treatment had more frequent grade 3 or higher adverse events compared to the placebo group.
A Georgia State University researcher is studying how to reduce tumor growth in lung cancer using a $2.3 million grant. The goal is to identify novel targets for treatment, as tumors become resistant to current therapies and promote new blood vessel formation.
A Penn study has identified a new molecular chain of events that highlights novel targets to treat prostate cancer, which also shows promise in treating lung cancer. The research found that PKCε overexpression can cause cancer progression and that blocking CXCL13-CXCR5 molecules may be a new cancer treatment.
Researchers found that adaptive radiation treatment significantly decreased the incidence of radiation pneumonitis in advanced lung cancer patients, while still slowing and controlling cancer growth. The study also showed no difference in cancer recurrence rates between the two groups.
A new analysis reveals heart failure patients experience worse survival rates than prostate cancer and breast cancer survivors, but better outcomes compared to lung cancer and ovarian cancer. The study highlights the continued burden of heart failure as a major public health concern.
Osimertinib significantly reduces lung cancer symptoms, including appetite loss, fatigue, and breathlessness, while improving global health status and enabling patients to perform daily activities. The drug demonstrates better activity, less toxicity, and improved quality of life compared to chemotherapy.
Researchers found that white blood cell counts at baseline and during therapy predict whether patients will respond to nivolumab treatment. A greater number and concentration of natural killer cells were associated with response to treatment.
Researchers found that certain lung cancer patients can continue treatment with immunotherapy even if the disease appears to be progressing, according to a study presented at ELCC 2017. The study used immune-related RECIST criteria, which take into account temporary tumour enlargement in patients taking immunotherapy.
A new study maps immune system components in early lung cancer, identifying potential targets for immunotherapy and suggesting a possible cure. The research reveals that early lesions are heavily infiltrated with immune cells, making immunotherapy a promising treatment option.
Patients with advanced NSCLC who received pre-treated checkpoint inhibitors had a 27% partial response rate to salvage chemotherapy, compared to 7% in those without pre-treatment. The study's findings suggest that checkpoint inhibitors may render tumor cells more sensitive to chemotherapy.
Researchers tracked lung tumour evolution in real-time to discover unstable chromosomes drive genetic diversity, increasing relapse risk. Circulating tumour DNA analysis reveals potential for personalised treatments to target resistant tumours.
Dr. Katerina A. Politi has made significant contributions to the understanding and treatment of EGFR mutant lung cancer. Her research has led to a paradigm-shift in the diagnosis and treatment of lung cancer, including the early adoption of molecular profiling.
Lung cancer patients treated with PD-1/PD-L1 checkpoint inhibitors are at increased risk of adverse events after receiving the seasonal influenza vaccination, according to a new study. The researchers observed an unusual high frequency of immune-related adverse events, including severe grade 3 or 4 irAEs, in this population.
Researchers found that patients with increased PD-1+ CD8 T cells in their blood after starting treatment experienced better clinical outcomes. The study's results suggest that monitoring activated T cells may help oncologists and patients decide whether to continue or combine treatments.
A study by researchers from the University of Georgia found that a spouse's cancer diagnosis results in a significant decline in household income, with men experiencing a 5% reduction and women experiencing a 9% reduction. The caregiver effect plays a crucial role in this decline, as spouses reduce their employment to support each other.
Rafal Dziadziuszko, a global leader in clinical thoracic oncology, has been awarded the Heine H. Hansen (HHH) Award by ESMO and IASLC for his lifetime contributions to lung cancer research and education globally.
Researchers developed a method to isolate EVs from blood samples, enabling rapid analysis and potential personalized anticancer treatments. The technique uses nanoprobes to capture EVs within 15 minutes, offering an alternative to invasive methods.
As the US HIV population ages, cancer incidence rates for AIDS-defining cancers are expected to decline due to effective treatment with modern antiretroviral therapies. However, frequencies of other cancers such as lung and prostate cancer are projected to increase.
A clinical trial of nivolumab found that 16% of patients with advanced nonsmall cell lung cancer survived at least five years, significantly higher than the standard 1-4% survival rate. Researchers hope to identify specific genetic markers linked to long-term response.
A combination of two drugs targeting molecular pathways controlled by the RAS gene has shown promise in treating RAS-driven lung, ovarian, and thyroid cancers. Patients with heavily treated cancers have experienced long-term clinical benefit from the treatment, including one patient on treatment for over two years.
Researchers used positron emission tomography (PET) to identify genetic cell mutations that cause lung cancer. Advanced image analysis technique, radiomics, non-invasively identified underlying cell mutations in NSCLC patients.
Researchers found that after reirradiation with intensity modulated proton therapy (IMPT), the majority of patients were free from local recurrence one year following treatment and few experienced severe side effects. Patients who received a higher dose of radiation had fewer local recurrences and improved progression-free survival.
Researchers found a combination of radiation therapy and immune checkpoint inhibitors to be effective in controlling tumors in metastatic lung cancer patients. Ten percent experienced severe treatment-related toxicity, but the treatment regimen showed promise for thoracic tumors, with median progression-free survival at 3.8 months.
African Americans and American Indians received less likely to receive potentially curative treatments for stage I non-small cell lung cancer (NSCLC), while Asian/Pacific Islanders had better survival rates. Patients who received definitive treatment had improved survival rates, regardless of race, age, or gender.
A new study presents evidence that intensity-modulated proton therapy (IMPT) is a safe and effective treatment option for patients with recurrent lung cancer. The study shows that over three-fourths of patients were free from local recurrence at one year following retreatment, with fewer than one in ten experiencing severe side effects.
Researchers found that SBRT is well-tolerated in elderly patients with early stage lung cancer, offering a viable curative treatment option. Patients who received definitive SBRT had high two-year survival rates of 73% for cancer-specific survival and 57% for overall survival.
A blood test analyzing specific biomarkers has been shown to detect lung cancer recurrences an average of six months before conventional imaging methods. This finding suggests that blood tests may be used in conjunction with CT and PET/CT scans to guide personalized treatment planning for patients with non-small cell lung cancer.
A free lung cancer screening in the Augusta area found more than double the cancer rate of previous screenings, with 3% of participants diagnosed with lung cancer. The majority of cases were caught early, with a 90% overall survival rate for those detected before symptoms appeared.
A new study shows that even with PD-1 blockade, tumor-specific T cells require CD28 co-stimulation to expand and restore effective immune responses. This finding suggests that only a subset of tumor-specific CD8 T cells will proliferate after PD-1-directed therapy.
A study of 151 patients with metastatic kidney cancer found that 85 had lung cancer metastasis, but only three had a primary lung cancer tumor that went undiagnosed. This discovery highlights the importance of medical oncologists and radiologists being aware of hidden lung cancers in kidney cancer patients.
Researchers at Boston University School of Medicine have found a genomic biomarker in the nasal passage that can accurately determine lung cancer likelihood. This non-invasive test may spare patients from costly and risky procedures by identifying those at low probability for having lung cancer.
A new study published in PLOS ONE found that people who spend time in jails and prisons are more likely to develop certain types of cancer than the general population in Ontario. The study also revealed that these individuals have a higher mortality rate from cancer, particularly for men.
Death rates from cancer are expected to decline faster in men than in women in Europe in 2017, with men predicted to fall by over 8% and women by around 4%. Lung cancer death rates will rise in women, but overall, fewer women than men will die from cancer.
Researchers at Emory University's Winship Cancer Institute have mapped a vast network of interactions between cancer proteins, revealing new ways to target cells with mutations. This approach identified a potential link between FDA-approved drug palbociclib and a commonly mutated gene in lung cancer cells.
A new study has found that radiotherapy for invasive breast cancer increases the risk of developing second primary lung cancer. The research, conducted in Taiwan, involved analyzing data from over 986,000 patients with breast cancer between 2000 and 2010. The results showed a significant increase in lung cancer incidence among women wh...
Researchers found that telephone-based smoking cessation counseling given shortly after lung cancer screening can help people stop smoking. The study enrolled 92 participants and showed an 8-person increase in verified quitters, with 17% in the counseling group compared to 4% in the control group.
Researchers at Cold Spring Harbor Laboratory have discovered that Importin-11 protects the anti-cancer protein PTEN from degradation by transporting it into the cell nucleus. This discovery suggests that the loss of Importin-11 may destabilize PTEN, leading to cancer development in lung, prostate, and other cancers.
A study by Cold Spring Harbor Laboratory researchers found that Importin-11 protects the anti-cancer protein PTEN from destruction, leading to cancer progression. Loss of Importin-11 may destabilize PTEN, predicting disease relapse and metastasis in prostate cancer patients.
A study suggests that limiting lung cancer screening to high-risk former smokers may improve cost-effectiveness. The most cost-effective scenario involves annual screening between ages 55 and 75 for persons who smoked over 40 pack-years and quit less than 10 years ago.
A study by American Cancer Society investigators found that only 3.9% of eligible current and former smokers received lung cancer screening in 2015, down from 4% in 2010. The authors call for education on screening benefits and risks to improve uptake among high-risk populations.
A study found that elderly non-small cell lung cancer (NSCLC) patients experiencing definitive radiation had a lower incidence of esophagitis compared to younger patients. The study, published in the Journal of Thoracic Oncology, showed an inverse correlation between age and rate of esophagitis for both grade levels.
The VHA lung cancer screening demonstration project found implementing a comprehensive program to be challenging, requiring new tools and patient care processes. The project also highlighted the need for dedicated patient coordination and accurate identification of patients for screening.
A recent study published in the Journal of Pain and Symptom Management found that lung cancer patients experiencing anxiety and depression have a significantly shorter length of survival. The research, conducted by the University of British Columbia and BC Cancer Agency, controlled for various factors to confirm this link.
Cancer mortality in the US declined by 20.1% from 240 to 192 deaths per 100,000 population between 1980 and 2014. Distinct clusters of counties with high cancer mortality rates were found, varying by type of cancer and region.
A new study reveals significant disparities in US cancer mortality rates among over 3,100 counties, highlighting unacceptable geographic variations and potential explanations for these differences. The analysis of 29 types of cancer shows that areas with high smoking rates and poor prevention programs tend to have higher mortality rates.
According to a study published in Journal of Thoracic Oncology, advanced stage Non-Small Cell Lung Cancer (NSCLC) patients receiving standard of care treatment have significantly longer overall survival rates compared to those not receiving treatment. This trend is observed across various stages of the disease.